Privia Health Group

PRVA · NASDAQ

$22.93+$0.49 (+2.18%)TodayMarket closed · Oct 20, 4:10 PM ET

Prev close $22.44

PRVA analyst rating

BuyConsensus of 10 analysts over the last 12 months. 90% rate it a buy.

Strong buy0
Buy9
Hold1
Underperform0
Sell0

12-month price target · 19 analysts

Average $31.88 (+39.0% upside)

Low: $24.24
Now: $22.93
High: $42.00

Upgrades and downgrades

The latest rating actions, newest first

PRVA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Barclays	May 26, 2026	Maintains	Equal-Weight	$25.00 → $24.00	59%
Canaccord Genuity	May 8, 2026	Maintains	Buy	$35.00 → $34.00	43%
Evercore ISI Group	Apr 8, 2026	Maintains	Outperform	$30.00 → $26.00	60%
Barclays	Mar 25, 2026	Maintains	Equal-Weight	$23.00 → $25.00	59%
Citigroup	Mar 3, 2026	Maintains	Buy	$34.00 → $32.00	44%
Truist Securities	Mar 2, 2026	Maintains	Buy	$31.00 → $33.00	37%
Canaccord Genuity	Feb 27, 2026	Maintains	Buy	$34.00 → $35.00	43%
RBC Capital	Jan 9, 2026	Initiates	Outperform	$31.00	67%
Stephens & Co.	Dec 4, 2025	Maintains	Overweight	$32.00	34%
JP Morgan	Nov 13, 2025	Maintains	Overweight	$32.00 → $33.00	54%

The case for and against

Updated Apr 28, 2026

Bull case

Privia Health Gr is well-positioned for long-term success due to their effective support of primary care physicians and their strong financial performance. The company's focus on value-based care and their solid partnerships with medical groups, health plans, and health systems have contributed to their record profitability and potential for future growth. With their strong leadership and strategic acquisitions, PRVA is expected to continue delivering strong financial results and leading the way in physician enablement services.

Bear case

Privia Health Gr is a physician enablement company with a strong presence in over 24 states. While the company's technology and service solutions are impressive, its agnostic approach and lack of visibility into the size and traction of its FFS and VBC books may hinder its short-term profitability. Additionally, the company's reliance on individual physicians for growth in existing markets and its asset-light model present risks. However, with the growing shift towards value-based care in the healthcare market, Privia's experienced management team and broad expertise position it well for future success.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.